[Federal Register Volume 86, Number 235 (Friday, December 10, 2021)]
[Notices]
[Page 70527]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2021-26717]



[[Page 70527]]

=======================================================================
-----------------------------------------------------------------------

INTERNATIONAL TRADE COMMISSION

[Investigation No. 337-TA-1100]


Notice of Commission Determination Not To Review an Initial 
Determination Granting a Motion for Return of a Bond; Certain 
Microfluidic Systems and Components Thereof and Products Containing 
Same

AGENCY: U.S. International Trade Commission.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: Notice is hereby given that the U.S. International Trade 
Commission (``Commission'') has determined not to review an initial 
determination (``ID'') (Order No. 46) of the presiding administrative 
law judge (``ALJ''), granting respondent Bio-Rad Laboratories, Inc.'s 
motion for return of the bond it posted during the period of 
Presidential Review.

FOR FURTHER INFORMATION CONTACT: Benjamin S. Richards, Esq., Office of 
the General Counsel, U.S. International Trade Commission, 500 E Street 
SW, Washington, DC 20436, telephone (202) 708-5453. Copies of non-
confidential documents filed in connection with this investigation may 
be viewed on the Commission's electronic docket (EDIS) at https://edis.usitc.gov. For help accessing EDIS, please email 
[email protected]. General information concerning the Commission may 
also be obtained by accessing its internet server at https://www.usitc.gov. Hearing-impaired persons are advised that information on 
this matter can be obtained by contacting the Commission's TDD terminal 
on (202) 205-1810.

SUPPLEMENTARY INFORMATION: On February 21, 2018, the Commission 
instituted this investigation based on a complaint filed by 10X 
Genomics, Inc. of Pleasanton, CA (``10X''). 83 FR 7491 (Feb. 21, 2018). 
The complaint alleged violations of section 337 of the Tariff Act of 
1930, as amended, 19 U.S.C. 1337, in the importation into the United 
States, the sale for importation, or the sale within the United States 
after importation of certain microfluidic systems and components 
thereof and products containing same by reason of infringement of one 
or more claims of U.S. Patent Nos. 9,644,204; 9,689,024; 9,695,468; and 
9,856,530. Id. The Commission's notice of investigation named as the 
sole respondent Bio-Rad Laboratories, Inc. of Hercules, CA (``Bio-
Rad''). Id. The Office of Unfair Import Investigations participated in 
this investigation. Id.
    On February 12, 2020, the Commission issued its opinion and final 
determination in this investigation, which found Bio-Rad in violation 
of section 337. The Commission also issued remedial orders on that date 
and set a bond of twenty-five percent (25%) of the entered value of the 
articles subject to the remedial orders during the period of 
Presidential review. Pursuant to that bond provision, Bio-Rad posted 
bond in the amount of $6,554.68.
    On July 26, 2021, Bio-Rad agreed to a settlement resolving the 
dispute in this investigation. Pursuant to a joint request by Bio-Rad 
and 10X, the Commission reviewed the settlement agreement and issued an 
order rescinding the remedial orders in this investigation on August 
25, 2021. See 86 FR 48441-42 (Aug. 30, 2021).
    On July 28, 2021, shortly after entering the settlement agreement 
with 10X, Bio-Rad moved without opposition for the return of its bond. 
On October 21, 2021, the presiding ALJ issued the subject ID, which 
granted Bio-Rad's motion. No petitions for review of that ID have been 
received.
    The Commission has determined not to review the subject ID. The 
bond at issue is ordered to be returned to Bio-Rad.
    The Commission vote for this determination took place on December 
6, 2021.
    The authority for the Commission's determination is contained in 
section 337 of the Tariff Act of 1930, as amended (19 U.S.C. 1337), and 
in Part 210 of the Commission's Rules of Practice and Procedure (19 CFR 
part 210).

    By order of the Commission.

    Issued: December 6, 2021.
Lisa Barton,
Secretary to the Commission.
[FR Doc. 2021-26717 Filed 12-9-21; 8:45 am]
BILLING CODE 7020-02-P